UV/Chlorine-BAC treatment of antidepressant drug in drinking water:efficacy,process optimization,and microbiological characterization

The environmental pollution caused by psychotropic drugs harms human health and has prompted a stronger emphasis on research into water treatment measures.The UV/Chlorine-biological activated carbon(BAC)combined process was employed in this study to treat amitriptyline(AMT),a typical psychotropic drug,in slightly contaminated drinking water.The removal efficiency of AMT in drinking water by UV/Chlorine and the feasibility of combining it with BAC were determined.The results demonstrated that the removal efficiency of 1μmol/L AMT could reach 98.5%of the 2.0 mg/L chlorine and UV treated for 30 min.A significant removal improvement of AMT was 10%45%compared to UV alone,Chlorine alone,and other oxidants combined,especially the SOUR(Specific Oxygen Uptake Rate),which was 57%-90%compared to other oxidants combined.Secondly,the optimal process parameters for UV/Chlorine-BAC treatment of slightly contaminated drinking water were a combination of UV exposure,chlorine dosage of 2 mg/L,and reaction times of i5 min followed by 30 min of BAC treatment.The AMT degradation,CODMn removal efficiency,and NO_(3)-N production was 88%,65%,and 95%,respectively.There was no significant effect on the number of microorganisms in the BAC medium,ensuring good long-term operation.Furthermore,an investigation was conducted to assess the influence of optimal process operation on the microbial community structure within BAC.This analysis unveiled a positive feedback loop in the colony architecture after implementing ideal process parameters.This study provides significant inspiration for addressing residual antidepressant issues using traditional drinking water treatment processes.

Risk factors for disease severity in COVID-19 patients: A single-center retrospective study

Background:The outbreak of coronavirus disease 2019(COVID-19)has posed a huge threat to human health.However,little is known regarding the risk factors associated with COVID-19 severity.We aimed to explore early-stage disease risk factors associated with eventual disease severity.Methods:This study enrolled 486 hospitalized,non-intensive care unit(ICU)-admitted adult patients with COVID-19(age≥18 years)treated at Wuhan Jinyintan Hospital,who were divided into three groups according to disease severity.The demographic,clinical,and laboratory data at admission and clinical outcomes were compared among severity groups,and the risk factors for disease severity were identified by multiple regression analysis.Results:Of 486 patients with COVID-19,405(83.33%)were discharged,33(6.71%)died outside of the ICU,and 48(7.20%)were still being treated in the ICU by the time the study period ended.Significant differences in age,lymphocyte counts,and the levels of procalcitonin,aspartate aminotransferase,and D-dimer(P<0.001 for all)among the three groups.Further analysis showed that older age,decreased lymphocyte counts,and increased procalcitonin,aspartate aminotransferase,and D-dimer levels were significantly associated with disease progression.Conclusion:Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)may impair the immune system,the blood coagulation system,and hepatic and cardiac function.Some clinical characteristics and laboratory findings can help identify patients with a high risk of disease severity,which can be significant for appropriate resource allocation during the COVID-19 pandemic.